Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.
about
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesPerspectives for therapeutic HPV vaccine developmentDNA vaccine for cancer immunotherapyActivation of target-tissue immune-recognition molecules by double-stranded polynucleotidesExperimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesOptimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potencyDNA vaccines: developing new strategies against cancer.FDA guidance on prophylactic DNA vaccines: analysis and recommendations.Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.DNA and RNA-based vaccines: principles, progress and prospects.DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challengeEffective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virionsInfection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model.Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodiesDNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosisCoexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosisEnhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GTargeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency.Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccinesTwo major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunizationEssential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infectionC-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritisThe signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.DNA vaccines against human immunodeficiency virus type 1 in the past decade.Systemic protein delivery by muscle-gene transfer is limited by a local immune response.DNA vaccines to attack cancerDNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsDNA vaccines, electroporation and their applications in cancer treatmentPredominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responsesCpG-depleted adeno-associated virus vectors evade immune detection.
P2860
Q24804837-15B6B93F-29E9-48D3-92DB-9DECE2FEADD6Q28069272-A0AA9A0F-B437-476D-BD41-8059583B1991Q28080919-A488661A-602F-4C89-85C4-794FC48FD150Q28571397-11123F6F-1F3D-43DE-B93C-7FA4F4605F4CQ30427591-27CA94A6-0F3E-4423-911B-C21CEEA98DD5Q33586294-7F5E1938-DC4F-46EF-ACB6-6DA02F3F1DC2Q33649019-B55F9D25-7548-4EFD-B4DC-32E79C20B880Q33756622-8A115A38-2B22-4C45-A5A5-60E562F4EA26Q33759465-58DD8F36-4CF7-4654-B7EE-DE28CE17AB8BQ33763297-B75C2760-6A8F-4D36-B26E-EAC02043C4F5Q33778143-DA6D156A-86A9-4738-876E-771EE393A425Q33782809-A29FE2BE-0902-4409-A397-52D23AF9360FQ33783789-6FCBB083-043F-435F-A124-317CBFD22DE0Q33784641-E4A722F2-FD8C-4821-9DA5-21B0DF487616Q33785150-692421D2-6D1E-4215-9185-F532AF84B16EQ33787271-69E4A389-1258-4D1E-ABF5-C5A932C368BAQ33813011-9E3960BA-76C0-43F4-8D5B-0E04F94099B8Q33849973-E5519ED7-36A6-4FB7-94DC-001D24231004Q33874465-A4D3EBF0-5802-4733-8BC8-203086AB38D2Q33912061-D3D79A01-1491-4B4A-B0FF-671982160DEAQ34004529-BE457575-9DEB-4CD9-AB86-C5D2377DE08EQ34116255-4C342244-0B50-4E04-9149-B32C3C3BFBBFQ34120701-53828C9E-16D4-48A9-A7A7-4BF4FB5A6086Q34342982-9037A149-EF2F-47D8-A5FC-098DE88BD0DBQ34382810-2B5E83AC-AD97-4E04-AE53-BF6DE8F5B692Q34555913-FC606636-1589-4579-8CDA-DB013DE1EA0EQ34601896-A0318DD4-1C02-4A92-822B-D876B1C937A7Q34976792-2930FBE5-B4B9-4E8F-BF2A-62195910C234Q35083138-DB9E41BA-C379-4DBA-8EE9-523590B1F365Q35126948-A8B75DA1-F59C-41EF-8B26-559674C4F7DEQ35271066-6785D52D-06A6-4CA8-9115-9A086A55E211Q35745831-7584433E-510D-4A65-956A-25BB0F077FA6Q35847626-2AFCACEA-98A7-443E-A718-1FDE7113613CQ35855143-578C483D-8ED2-4542-B16E-BD86AC3C7166Q35940696-2D40D642-5B6B-4184-A311-C1054990F06AQ36256459-CA647AEB-1102-4FF6-8993-A20C6F2E8C76Q36401759-76ED6225-5664-4B37-8481-CA8DCB01BB7FQ36489528-E2E5F7D3-DCB8-456A-BE3B-61789F41AD20Q36539092-36DB62FD-0ED0-4973-BD7E-D6C7B77A1181Q36966955-88CEA105-C423-4DC9-80B7-EF5A98A986F8
P2860
Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@ast
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@en
type
label
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@ast
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@en
prefLabel
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@ast
Priming of cytotoxic T lymphoc ...... ntigen transfer from myocytes.
@en
P2093
P2860
P356
P1433
P1476
Priming of cytotoxic T lymphoc ...... antigen transfer from myocytes
@en
P2093
A Friedman
J J Donnelly
M J Caulfield
P2860
P2888
P304
P356
10.1007/BF03401683
P407
P577
1997-06-01T00:00:00Z